Key result
Inactivated EV71 whole-virus vaccines demonstrated high safety and immunogenicity, with protective efficacies over 90% against EV71-associated HFMD and over 80% against other EV71-associated diseases.
Why the study?
Does the inactivated EV71 whole-virus vaccine prevent EV71-associated HFMD and other diseases in children?
Population
Children in Asian countries (mainland China, Taiwan, Singapore)
Design
Review
Authors
Loading...
May inform pediatric EV71 vaccination strategies in endemic areas; leaves open long-term durability and implementation questions.
Does the inactivated EV71 whole-virus vaccine prevent EV71-associated HFMD and other diseases in children?
Effect estimate: >90% protective efficacy
Inactivated EV71 whole-virus vaccines demonstrate high safety, immunogenicity, and >90% protective efficacy against EV71-associated HFMD in Phase III trials.
Liang et al. (2014) conducted a review in Enterovirus 71 (EV71) associated hand, foot and mouth disease (HFMD). Inactivated EV71 whole-virus vaccines was evaluated on EV71-associated HFMD (>90% protective efficacy). Inactivated EV71 whole-virus vaccines demonstrated high safety and immunogenicity, with protective efficacies over 90% against EV71-associated HFMD and over 80% against other EV71-associated diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: